GlaxoSmithKline

GSK
Real-time CHI-X EUROPE LIMITED. - 04/03 11:30:00 am
1492.2GBp
+0.30%

GlaxoSmithKline : Description Report of Foreign Issuer

Envoyer par e-mail
02/21/2020 | 03:28 pm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2020

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Transfer of 10,720 Ordinary Shares between accounts for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,720

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-20

f)

Place of the transaction

N/A

1. Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Transfer of 10,838 Ordinary Shares to spouse for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,838

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-20

f)

Place of the transaction

N/A

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Whyte

b)

Position/status

PCA of Ms V Whyte (Company Secretary)

c)

Initial notification/amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Receipt of 10,838 Ordinary Shares from spouse for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,838

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2020-02-20

f)

Place of the transaction

N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: February 21, 2020

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc

Disclaimer

GSK - GlaxoSmithKline plc published this content on 21 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 February 2020 14:28:01 UTC

Envoyer par e-mail